According to a recent market study published by Growth Market Reports titled, "Global Orally Disintegrating Tablets Market by drug class, disease indication, and by Region: Size, Share, Trends and Opportunity Analysis, 2017-2027", the market was valued at USD 11,988 Million in 2019 and is expected to grow at a healthy growth rate of 10.18% by the year 2027. The ODT market is anticipated to grow significantly during forecast period. ODTs are gaining tremendous importance as compared to other dosage form owing to their benefits. ODTs have better stability, easier production process, convenient packing size, bioavailability, rapid onset of action and high patient compatibility.

Global orally disintegrating tablets market has been fragmented based on drug class, disease indications, and by regions. In terms of drug class, the global ODT market is categorized as antipsychotics, anti-epileptics, CNS stimulants, anxiolytics, antiparkinsonian drugs, anti-hypertensive, NSAIDS, anti-allergy drugs, proton pump inhibitors, vaccine ODT and others. Based on disease indication, the market is classified as central nervous system (CNS) diseases, gastrointestinal (GI) diseases, cardiovascular (CVS) diseases, allergy and others. By region ODT market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa (MEA). North America region is further bifurcated into countries such as the U.S., and Canada. The Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, the Asia Pacific is further segmented into, China, Japan, South Korea, Australia, Southeast Asia, and Rest of Asia Pacific. The European region is further categorized into Germany, France, Italy, the U.K., Spain, Russia, and the Rest of Europe, and the MEA region is further divided into Saudi Arabia, South Africa, UAE, and the Rest of MEA.

Request a free sample copy: https://growthmarketreports.com/request-sample/153

The effect of COVID-19 pandemic situation has led to the closure of several non-essential businesses reducing the demand for industrial goods in the world, which in turn, is affecting several industries worldwide. On the other hand, the COVID-19 pandemic is encouraging production activities across orally dissolving tablets manufacturing units worldwide, the demand for ODTs has surged throughout the pandemic. As people are inclining towards ODTs during the lockdown period for their health benefits. The global supply chain has slowed down due to restrictions on national borders. Regarding the ODTs market as demand has been growing at normal growth rate during pandemic situation. Additionally, the ODT production has grown and the market is expected to witness significant growth post COVID.

As per Growth Market Reports industry analyst Vidya Jadhav, “The rising old population, and increasing prevalence of diseases and growing number of mentally disabled people many countries are anticipated to drive the growth of ODT market significantly. Moreover, the Emerging Demand from Developing Countries and diseases such as coronavirus (COVID-19) are anticipated to create lucrative opportunity during forecast period.”

Key Takeaways from the Study:

  • Asia Pacific is expected to continue dominating the orally disintegrating tablets market due to the increasing old population owing to the rising life expectancy in the region.
  • On the basis of drug class, the orally disintegrating tablets market is segmented into anti-psychotics, anti-epileptics, CNS stimulants, anxiolytics, anti-parkinsonian drugs, anti-hypertensive, NSAIDS, anti-allergy drugs, proton pump inhibitor, vaccine ODT, others. The anxiolytics segment is expected to hold a significant share of the market and is projected to expand at a substantial CAGR during the forecast period.
  • Growing healthcare expenditure in various countries such as the US, Canada, and Germany is expected to help people get appropriate treatment for various central nervous disorders and CVDs.

Report Scope:

Report Metric

Details

Market Value in 2019

USD 11,988 Million

Market Growth Rate (from 2021 to 2027)

10.18%

Historical Data

2017 & 2018

Base Year

2019

Forecast Period

2020 – 2027

Market Segments

Drug Class, Disease Indication

Regional Scope

North America, Europe, Latin America, Asia Pacific, Middle East & Africa (MEA)

Country Scope

U.S., Canada, Brazil, Mexico, Rest of Latin America, China, Japan, South Korea, India, Australia, Southeast Asia, Rest of Asia Pacific, Germany, France, Italy, U.K., Spain, Russia, Rest of Europe, Saudi Arabia, South Africa, UAE and Rest of MEA.

Key Companies Profiled

Alkem Labs, Amneal Pharmaceuticals LLC, Apotex Inc., Aurobindo Pharma, Bausch Health Companies Inc., Eli Lilly and Company, GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, Viatris Inc. (Mylan N.V. and Pfizer's Upjohn)

Customization Scope

Report customization available on request

Pricing and Purchase Options

Avail tailor-made purchase options to meet your research requirements.

Target Audience:

  • Supply-side: ODT manufacturers, raw material suppliers, primary respondents, and distributors,
  • Demand Side: People using ODT as medications, ODT retailers and suppliers.
  • Regulatory Side: Concerned government authorities, commercial research & development (R&D) institutions, and other regulatory bodies.
  • Associations and Industry Bodies: Medical & Professional Associations, World Health Organizations (WHO), Drug Information Association (DIA), National Library of Medicine, Pan American Health Organization (PAHO), World Trade Organization (WTO)